Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofazimine in Pulmonary Mycobacterium Avium Disease
NCT02968212Phase 2Active, not recruiting
- Sponsor
- Oregon Health & Science University
- Start
- Apr 2017
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clofazimine in Mycobacterium avium complex lung disease (2 arms), sponsored by Oregon Health & Science University. Primary endpoint: Change from Baseline sputum culture at 24 weeks. Started Apr 2017; status: active, not recruiting.
02
Drugs
clofazimine
03
Conditions
Mycobacterium avium complex lung disease
Beyond the preview
Go deeper on NCT02968212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968212.